second
look
select
compound
give
new
life
sever
abandon
therapi
new
applic
exist
drug
one
exampl
provid
chloroquin
dismiss
antimalari
treatment
find
new
applic
clinic
manag
autoimmun
diseas
tumour
nonmalari
infect
use
chloroquin
clinic
manag
viral
infect
first
consid
basi
effect
drug
test
investig
antiretrovir
us
previous
analys
report
effect
chloroquin
replic
sever
virus
conclud
drug
studi
broad
spectrum
antivir
agent
emerg
viral
infect
rel
well
toler
cheap
immedi
avail
worldwid
weak
base
capabl
accumul
within
cellular
organel
chloroquin
appear
capabl
interf
phdepend
step
replic
sever
virus
mechan
viral
inhibit
chloroquin
inhibit
polynucleotidyl
transferas
howev
consid
chloroquin
studi
promis
vitro
antisar
agent
recent
enter
clinic
trial
chikungunya
fever
broadspectrum
antivir
effect
chloroquin
deserv
particular
attent
time
sever
case
avian
influenza
viru
transmiss
human
poultri
avail
antivir
drug
fundament
prepar
evalu
effect
vaccin
chloroquin
inhibit
type
b
influenza
virus
first
describ
concentr
employ
studi
howev
high
allow
theoret
transposit
invivo
set
anecdot
report
clinic
benefit
deriv
relat
compound
ie
quinin
date
back
spanish
influenza
pandem
howev
last
year
antiinfluenza
viru
effect
chloroquin
clinic
achiev
concentr
studi
view
possibl
applic
drug
clinic
manag
influenza
investig
still
done
topic
exampl
mechan
orthomyxoviru
inhibit
chloroquin
uncertain
clinic
achiev
concentr
adopt
recent
studi
well
effect
chloroquin
field
isol
includ
avian
strain
potenti
transmitt
human
report
result
initi
evalu
suscept
chloroquin
human
avian
influenza
virus
suscept
chloroquin
appear
depend
ph
requir
virus
electrostat
potenti
haemagglutinin
subunit
involv
viruscel
fusion
accordingli
antivir
effect
exert
earli
step
viru
replic
first
test
effect
chloroquin
lowpathogen
lp
viru
isol
poultri
itali
found
chloroquin
dosedepend
inhibit
viral
cytopath
effect
effect
concentr
cell
infect
viru
approx
tissu
cultur
infect
dose
ml
fig
although
valu
rather
high
inhibitori
concentr
match
blood
concentr
report
individu
acut
antimalari
treatment
inhibitori
effect
confirm
use
quantit
revers
transcritptas
realtim
pcr
qrrtpcr
fig
ooi
et
al
recent
report
chloroquin
inhibit
human
virus
valu
rang
investig
whether
discrep
inhibitori
valu
report
due
type
viru
differ
condit
method
adopt
test
effect
chloroquin
replic
recent
human
viral
isol
condit
similar
adopt
avian
influenza
viru
use
test
inhibit
viral
cytopathogen
found
chloroquin
inhibit
viru
inhibit
confirm
use
qrrtpcr
similar
condit
lower
moi
thu
confirm
result
ooi
et
al
assay
adopt
author
employ
lower
moi
routin
use
group
result
obtain
virus
show
similar
drug
suscept
human
strain
full
agreement
ooi
et
al
respons
clinic
achiev
drug
concentr
avian
strain
data
shown
data
suggest
pronounc
inhibitori
effect
chloroquin
human
virus
avian
viru
replic
sinc
chloroquin
thought
interfer
phdepend
step
life
cycl
sever
virus
us
report
differ
ph
requir
influenza
virus
infect
differ
avian
speci
investig
whether
respons
influenza
virus
chloroquin
might
depend
differ
ph
requir
human
avian
virus
thu
analys
respons
human
viru
good
chloroquin
respond
avian
viru
poor
chloroquin
respond
ammonium
chlorid
mm
lysosomotrop
agent
known
increas
ph
intracellular
vesicl
result
show
good
respons
chloroquinesensit
viru
inhibit
viral
cytopathogen
inhibit
condit
describ
convers
lower
chloroquinesensit
viru
associ
lack
respons
data
shown
observ
rais
hypothesi
cellular
ph
might
critic
factor
chloroquin
inhibit
influenza
viru
explor
possibl
action
chloroquin
test
two
avian
virus
whose
haemagglutinin
differ
two
amino
acid
posit
ie
residu
subunit
residu
latter
ha
subunit
mediat
fusion
process
display
differ
ph
requir
two
viral
strain
show
mark
discrep
respons
chloroquin
particular
viru
shown
rel
independ
ph
increas
viru
insensit
clinic
achiev
chloroquin
concentr
contrast
chloroquin
exert
inhibitori
effect
replic
although
respons
viru
chloroquin
lower
viru
differ
ph
requir
two
virus
confirm
differ
respons
inhibit
inhibit
result
rais
hypothesi
chloroquin
inhibit
phdepend
event
involv
ha
explor
possibl
isoelectr
point
calcul
virus
use
present
studi
electrostat
potenti
map
protein
surfac
model
obtain
homolog
crystal
structur
match
subtyp
repres
result
show
neg
correl
isoelectr
point
chloroquin
vitro
r
p
fig
instead
correl
found
isoelectr
point
p
data
shown
although
virus
studi
belong
differ
subtyp
chloroquineresist
virus
independ
subtyp
show
mark
neg
surfac
potenti
chloroquinesensit
virus
fig
virus
intermedi
drug
sensit
show
intermedi
characterist
fig
conclud
structur
determin
associ
respons
influenza
virus
chloroquin
hypothesi
ph
depend
inhibitori
action
chloroquin
correct
time
drug
inhibit
match
viruscel
fusion
earli
step
viru
replic
occur
endosom
requir
low
ph
approx
ph
sever
influenza
virus
shown
previou
studi
assay
detect
antivir
effect
adopt
first
part
studi
design
allow
multipl
cycl
viral
replic
design
timeofaddit
experi
use
chloroquinesensit
human
viru
chloroquin
ad
viru
adsorpt
onto
cell
ie
time
andor
h
postinfect
use
qrrtpcr
found
inhibitori
effect
chloroquin
highest
drug
ad
inhibit
viral
replic
correspond
inhibit
replic
correspond
wherea
inhibitori
activ
complet
lost
time
correct
chloroquin
inhibit
influenza
replic
novel
mechan
therefor
exert
addit
effect
combin
oseltamivir
inhibit
neuraminidas
activ
late
stage
viral
replic
cycl
test
hypothesi
human
virusinfect
cell
treat
differ
chloroquin
concentr
presenc
absenc
oseltamivir
nm
virusinfect
cell
also
incub
oseltamivir
alon
nm
isobologram
analysi
show
two
drug
exert
addit
effect
sum
fic
data
shown
result
provid
evid
chloroquin
inhibit
viral
replic
mechan
differ
one
major
antiinfluenza
drug
result
far
obtain
suggest
chloroquin
inhibit
replic
influenza
virus
requir
low
ph
proper
fusion
activ
antivir
effect
occur
earli
stage
viral
replic
support
evid
come
sustain
inhibitori
effect
chloroquin
virus
whose
haemagglutinin
found
requir
low
ph
fusion
activ
common
characterist
surfac
potenti
isoelectr
point
chloroquinesensit
virus
timeofaddit
experi
viru
chloroquin
found
inhibit
number
cellular
process
depend
low
ph
might
anyway
interfer
viral
replic
exampl
drug
found
inhibit
viral
nucleotidyl
transferas
integras
chloroquin
inhibit
influenza
rnadepend
rna
polymeras
time
viral
inhibit
would
consist
observ
present
studi
rna
replic
occur
nucleu
later
stage
base
bioinformat
studi
recent
hypothes
chloroquin
might
inhibit
udp
n
acetylglucosamin
transferas
limit
enzym
sialic
acid
synthesi
specif
issu
address
nonetheless
antivir
effect
chloroquin
report
due
inhibit
udpn
acetylglucosamin
transferas
drug
like
antagon
antivir
effect
neuraminidas
inhibitor
oseltamivir
act
detach
sialic
acidbound
virion
parent
cell
render
oseltamivir
inhibit
unnecessari
instead
chloroquin
found
present
studi
exert
antivir
effect
addit
oseltamivir
chloroquin
weak
base
known
affect
acid
vesicl
lead
dysfunct
sever
protein
shown
inhibit
differ
virus
requir
phdepend
step
entri
result
timeofaddit
experi
perform
present
studi
use
recent
epidem
isol
human
viru
consist
chloroquin
inhibit
phdepend
step
occur
earli
phase
influenza
viru
replic
influenza
virus
enter
target
cell
fusion
viral
cell
membran
endosom
ph
approx
ph
although
viru
variant
replic
well
also
higher
ph
valu
previou
paper
differenti
growth
sensit
two
natur
occur
variant
viru
isol
mallard
turkey
increas
ph
valu
shown
correl
differ
fusion
properti
sinc
chloroquin
appear
mimic
effect
observ
two
virus
ph
increas
data
support
hypothesi
step
viru
replic
inhibit
clinic
relev
chloroquin
concentr
lowph
depend
haemagglutininmedi
viruscel
fusion
agreement
evid
obtain
author
much
higher
concentr
use
studi
correspond
antivir
effect
isoelectr
point
ie
ha
subunit
mediat
fusion
process
also
consist
mechan
acid
ph
endosom
compart
also
activ
influenza
viru
ion
channel
promot
uncoat
influenza
viru
endosom
howev
involv
possibl
target
antivir
effect
chloroquin
unlik
sinc
aminoacid
differ
observ
transmembran
region
ionchannel
domain
two
avian
virus
differ
chloroquin
sensit
alreadi
report
although
comprehens
studi
variat
fusion
ph
requir
influenza
virus
ha
subtyp
isol
differ
host
avail
sever
author
document
threshold
ph
ha
conform
chang
viruscel
fusion
occur
strainspecif
interestingli
virus
show
highest
chloroquin
sensit
also
display
highest
isoelectr
point
thu
relationship
isoelectr
point
respons
ph
appar
howev
broad
studi
relat
surfac
electrostat
potenti
inactiv
ph
would
requir
analys
molecular
detail
haph
interplay
analys
viru
product
exposur
chloroquin
possibl
chang
surfac
potenti
virus
render
resist
chloroquin
long
exposur
drug
also
necessari
although
associ
variabl
consid
equival
causat
result
present
studi
strongli
suggest
ph
critic
determin
antivir
activ
chloroquin
regul
virushost
cell
interact
potenti
use
compound
antiinfluenza
drug
take
consider
possibl
even
within
subtyp
differ
strain
may
present
significantli
diverg
sensit
chloroquin
consequ
differ
ph
requir
moreov
sensit
chloroquin
may
vari
differ
cell
popul
suscept
influenza
viru
infect
depend
differ
capabl
endosom
acidif
mutat
affect
electrostat
potenti
protein
subunit
variou
isol
viru
could
also
relev
factor
care
evalu
hypothesis
potenti
clinic
utilis
chloroquin
influenza
virus
madin
darbi
canin
kidney
mdck
cell
obtain
american
type
cultur
collect
follow
virus
use
studi
two
recent
human
strain
anew
four
lp
avian
influenza
virus
viru
titrat
perform
tissu
cultur
infecti
dose
mdck
cell
describ
viru
stock
aliquot
store
use
virus
istituto
superior
di
iss
repositori
viru
infect
mdck
cell
monolay
carri
accord
standard
procedur
chloroquin
phosphat
diethylamino
amino
quinolin
phosphat
sigma
oseltamivir
kind
gift
roch
use
posit
control
hour
incub
virusinfect
cell
differ
concentr
test
compound
appropri
condit
pool
aliquot
supernat
contain
free
virus
subject
rna
extract
qrrtpcr
onestep
qrrtpcr
assay
employ
make
use
minor
groov
binder
mgb
probe
technolog
previous
describ
briefli
viral
rna
extract
infect
cell
supernat
qiamp
viral
rna
mini
kit
qiagen
gmbh
hilden
germani
amplifi
rrtpcr
use
primer
probe
target
highli
conserv
region
matrix
gene
influenza
type
virus
influenza
matrix
rna
also
vitro
transcrib
correspond
dna
templat
clone
plasmid
vector
previous
describ
use
standard
rna
gener
standard
curv
quantif
vrna
cell
supernat
cellsml
mdck
cell
growth
medium
seed
well
microtit
plate
cell
monolay
confluent
cultur
medium
remov
cell
wash
twice
serumfre
mem
type
influenza
virus
studi
contain
inocul
well
plate
incub
hour
humidifi
air
viral
suspens
remov
cell
wash
two
time
fresh
medium
contain
tpcktrypsin
chloroquin
differ
concentr
mm
ad
cultur
well
triplic
antivir
activ
cytotox
measur
base
viabil
cell
infect
mock
infect
influenza
virus
presenc
variou
concentr
test
compound
one
three
day
depend
kinet
cytopathogen
infect
number
viabl
cell
quantifi
tetrazoliumsaltbasedcolorimetr
method
celltit
aqueou
one
solut
kit
promega
netherland
measur
antiinfluenza
effect
chloroquineoseltamivir
drug
combin
cell
pellet
resuspend
media
contain
increas
concentr
antimalari
presenc
absenc
oseltamivir
fraction
inhibitori
concentr
fic
calcul
ratio
effect
concentr
drug
combin
drug
drug
alon
effect
consid
addit
sum
fic
previous
describ
monolay
mdck
cell
plate
infect
medium
contain
approxim
subtyp
hour
adsorpt
cell
monolay
wash
twice
serumfre
mem
incub
fresh
medium
contain
tpcktrypsin
chloroquin
concentr
chloroquin
ad
time
infect
four
differ
time
point
thereaft
eight
hour
postinfect
time
point
progeni
viru
supernat
deriv
first
replic
cycl
cell
supernat
collect
viral
rna
extract
antivir
activ
determin
use
qrrtpcr
describ
hemagglutinin
gene
virus
sequenc
use
genespecif
primer
previous
describ
sequenc
data
far
unpublish
deposit
genbank
time
public
present
articl
threedimension
model
virus
use
present
studi
obtain
homolog
model
use
swiss
model
web
server
use
templat
structur
match
subtyp
repres
deposit
protein
data
bank
pdb
hydrogen
ad
use
vegazz
univers
milan
itali
structur
visualis
use
swiss
pdb
viewer
spdbv
program
swiss
institut
bioinformat
coulomb
potenti
map
protein
surfac
use
spdbv
use
default
rel
dielectr
constant
solvent
water
inform
algorithm
adopt
program
avail
detail
onlin
descript
program
ldt
develop
viru
detect
assay
particip
experiment
design
manuscript
draft
particip
gener
design
studi
data
analysi
molecular
model
draft
manuscript
lc
particip
experiment
design
data
analysi
manuscript
draft
sp
prepar
sequenc
viral
sampl
involv
assay
antivir
activ
ev
sn
ddo
conduct
assay
antivir
activ
id
coordin
virolog
activ
particip
experiment
design
ac
conceiv
coordin
entir
studi
